Developer docs
API playgroundTry for free, no card

Search company profiles

Aiforia

Full company profile

uuid0000fpz

Namestring
Aiforia
Legal namestring
Aiforia Technologies Oyj
Websiteurl
aiforia.com
Company typeenum
Public
Founded yearint
2013
Descriptiontext

Aiforia Technologies Oyj (Nasdaq Helsinki: AFORIS) is a Finland-based public company founded in 2013 that develops deep learning AI solutions for digital pathology image analysis. The company sells a portfolio of CE-IVD marked clinical AI applications covering breast cancer (Ki-67, HER2, ER/PR scoring), lung cancer (PD-L1), prostate cancer biopsy analysis, gastric cancer, colorectal cancer (QuantCRC prognostic tool), and lymph node metastasis detection. These clinical applications run on a proprietary Foundation Engine designed for robust operation across variable sample quality, staining, and scanner conditions, and are delivered through the cloud-based Aiforia Platform with an integrated Clinical Suite Viewer. Aiforia also offers Aiforia Create, a collaborative cloud environment that allows pathologists and scientists to train custom deep learning models without prior AI expertise, alongside research solutions for preclinical and academic workflows and a veterinary diagnostics offering.

Revenue is generated primarily through annual and multi-year subscriptions for clinical AI deployments and research platform access, supplemented by professional services for enterprise implementations. Pricing is quote-based and tied to deployment scale, user counts, and integration requirements. The company pursues a dual go-to-market of direct enterprise field sales (targeting hospital pathology departments, academic medical centers, and pharma/biotech customers such as AP-HP, Mayo Clinic, Sanofi, Boehringer Ingelheim, and Charles River Laboratories) and channel partnerships with major healthcare IT vendors (Siemens Healthineers, Dedalus Group, Proscia, Tribun Health) plus regional partners in Canada (Quorum Technologies) and South Korea (Urban Datalab). The company maintains wholly-owned subsidiaries in France (Paris) and the United States (Cambridge, MA) to support European and North American commercial operations.

The company holds ISO 13485, ISO 27001, SOC 2 Type II, IVDR, GDPR, and HIPAA-aligned certifications and operates with a headcount of 51-100 employees. Management has disclosed a target of 50 clinical accounts and financial independence by end of 2027, alongside an ambition to cover approximately 80% of pathologists' diagnostic workflow by 2030.

Short descriptiontext

Aiforia Technologies Oyj (Nasdaq Helsinki: AFORIS) develops CE-IVD marked deep learning AI solutions for digital pathology, serving clinical laboratories, pharmaceutical and biotech firms, and academic medical centers across Europe, North America, and select Asia-Pacific markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersHelsinki, Finland
HQ citystring
Helsinki
HQ countrystring
Finland
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital pathology AI, clinical decision support, medical image analysis, cancer diagnostic software, deep learning pathology
Industry3 codes
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
NAICS code3 codes
  • Software Publishers5132
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services5182
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Services-Prepackaged Software7372
Product category
Digital Pathology AI Software
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Clinical AI Solutions Subscription
TypeSubscription Recurring
Description

SaaS subscription model providing access to CE-IVD marked AI diagnostic applications for clinical pathology laboratories. Revenue generated through software subscriptions with recurring annual or multi-year billing.

aiforia.com
2Research Solutions Platform
TypeSubscription Recurring
Description

Aiforia Create platform access for pharmaceutical researchers, biotech companies, and academic institutions to develop and deploy custom AI models for preclinical and clinical research applications.

aiforia.com
3Professional Services
TypeProfessional Services
Description

Implementation, training, and support services for enterprise deployments, particularly through strategic partnerships with Siemens Healthineers and Dedalus.

in.investing.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels7 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Pricing details2 tiers
1Enterprise clinical subscription
ModelSubscriptionBilling cadenceAnnual
Notes

Quote-based pricing for clinical AI solutions targeting pathology laboratories. Pricing varies based on deployment scale, number of users, and integration requirements.

aiforia.com
2Research platform subscription
ModelSubscriptionBilling cadenceAnnual
Notes

Aiforia Create platform subscription for researchers and scientists to develop custom AI models. Pricing based on team size and usage.

aiforia.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 7 records shown
1Aiforia® Clinical Suites
Description

CE-IVD marked AI solutions for clinical diagnostics including Breast Cancer Suite, Lung Cancer Suite, Prostate Cancer Suite, Gastric Suite, and Lymph Node Metastasis detection

aiforia.com
+6 more records
Core offering1 text field

Aiforia develops and sells cloud-based deep learning AI software for digital pathology image analysis. Its offering consists of two main product lines: (1) CE-IVD marked Clinical Suites providing AI-driven diagnostic workflows for breast, lung, prostate, gastric, and colorectal cancer plus lymph node metastasis detection, and (2) Research Solutions including the Aiforia Create no-code AI model development platform for preclinical, pharmaceutical, and academic research. Both are powered by the proprietary Foundation Engine and delivered as SaaS to pathology laboratories, pharmaceutical/biotech companies, and academic medical centers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Clinical sector revenue grew 68% year-over-year in Q4 2025
+4 more records
Product overview1 text field

Aiforia offers a cloud-based AI platform for digital pathology with two main product lines: Clinical Solutions (CE-IVD marked AI diagnostic applications) and Research Solutions (for preclinical/academic use). The Clinical Suite portfolio includes specialized AI solutions for breast cancer, lung cancer, prostate cancer, gastric cancer, colorectal cancer (QuantCRC), and lymph node metastasis detection—all powered by the proprietary Foundation Engine technology. Aiforia® Create serves as the AI development tool enabling users to build custom deep learning models without coding. The platform integrates with various laboratory information systems and image management platforms through APIs and partnerships with Dedalus, Proscia, Siemens Healthineers, and Tribun Health.

Product and service2 records
1Aiforia Clinical Suites
CategoryClinical Diagnostic AI Software
Description

Comprehensive portfolio of CE-IVD marked AI solutions for clinical diagnostics in digital pathology, providing fully automated case-centric workflows with a wide range of AI models and an optimized interactive user interface for pathology laboratories.

2Aiforia Breast Cancer Suite
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-04-16
Description

Aiforia selected as AI partner for the PROSTIA project led by AP-HP, deploying its CE-IVD-marked prostate cancer diagnostic solution across AP-HP pathology sites. Project expands from 2 hospitals (Bicêtre and Saint-Louis) to 7 total sites, covering all 3,000 prostate biopsy cases per year. Two-year initiative funded by Bpifrance through France 2030 program to evaluate medical, operational, and economic impacts of AI in pathology workflows.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-03-10
Description

Non-exclusive partnership integrating Aiforia's AI-powered diagnostic applications with Proscia's Concentriq platform, enabling seamless AI-driven digital pathology workflows for anatomic pathology laboratories globally. Both companies have joined Proscia's Ready partner alliance and will showcase innovations at USCAP 115th Annual Meeting in March 2026.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-09-09
Description

Strategic partnership with Siemens Healthineers to expand availability of Aiforia's AI applications for clinical diagnostics across European diagnostic laboratories. Siemens Healthineers affiliates will co-market and sell Aiforia's digital pathology solutions as part of their broader portfolio, leveraging their strong regional presence and integration capabilities.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-09-01
Description

Strategic alliance to integrate Aiforia's AI solutions into Dedalus' InVitro Anatomic Pathology Information System. The partnership aims to accelerate adoption of Aiforia's AI solutions among Dedalus' existing customer base of 5,700 laboratories and diagnostic centers worldwide by providing ready-made integration.

Strategic tierRegionalTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-03-18
Description

Partnership to expand AI-assisted pathology solutions in Canada, improving digital pathology workflows and enhancing patient care by making AI solutions more accessible in the Canadian healthcare sector.

Strategic tierRegionalTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-10-08
Description

Partnership to promote AI-based digital pathology in South Korea, improving diagnostic accuracy, workflow efficiency, and patient care across South Korean hospitals.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Pure-play AI digital pathology company offering FDA-authorized clinical AI solutions and a research platform. Directly comparable to Aiforia in target market (clinical pathology labs and pharma), technology (deep learning on whole-slide images), and business model (SaaS subscriptions).

TypeDirect peer
Description

AI-powered cancer diagnostics platform for pathology, with CE-marked clinical products deployed across European hospitals. Closely comparable to Aiforia in CE-IVD clinical product portfolio, channel partnerships with tier-1 diagnostics vendors, and target customer segments.

TypeDirect peer
Description

AI pathology company combining diagnostic products with biopharma services. Comparable to Aiforia across clinical AI applications, research/AI development tools (AISight), and pharmaceutical R&D use cases.

TypeDirect peer
Description

AI-for-drug-discovery and pathology company serving both biopharma and clinical diagnostic customers. Comparable to Aiforia in using deep learning on pathology images for both pharma research and clinical decision support.

TypeEmerging player
Description

Digital pathology platform vendor whose Concentriq platform integrates with Aiforia's AI solutions. Both partner and partial competitor with overlapping enterprise pathology customer base and cloud-based delivery model.

TypeEmerging player
Description

Digital pathology image management vendor (CaloPix) that integrates with Aiforia through CaloPix Connect. Adjacent competitor and integration partner in enterprise pathology workflows.

TypeBroad incumbent
Description

Global diagnostics incumbent with a broad digital pathology portfolio spanning hardware, software, and AI. Comparable as a broader competitor with much greater scale and ability to bundle AI offerings with installed hardware base.

TypeBroad incumbent
Description

Healthcare technology incumbent with IntelliSite digital pathology solution. Comparable as an enterprise-scale alternative that bundles whole-slide imaging, workflow software, and AI applications across hospital systems.

TypeBroad incumbent
Description

Major pathology equipment and software vendor (Aperio) now part of Danaher's diagnostics platform. Comparable as an established competitor in clinical pathology workflow infrastructure.

TypeEmerging player
Description

Pathology image analysis software vendor with both research (Halo) and emerging clinical offerings. Comparable in serving pharma and academic research customers and providing quantitative AI image analysis tooling.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers16 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aiforia

Digital Pathology AI Softwareaiforia.com

Aiforia Technologies Oyj (Nasdaq Helsinki: AFORIS) develops CE-IVD marked deep learning AI solutions for digital pathology, serving clinical laboratories, pharmaceutical and biotech firms, and academic medical centers across Europe, North America, and select Asia-Pacific markets.

What Aiforia does

Aiforia Technologies Oyj (Nasdaq Helsinki: AFORIS) is a Finland-based public company founded in 2013 that develops deep learning AI solutions for digital pathology image analysis. The company sells a portfolio of CE-IVD marked clinical AI applications covering breast cancer (Ki-67, HER2, ER/PR scoring), lung cancer (PD-L1), prostate cancer biopsy analysis, gastric cancer, colorectal cancer (QuantCRC prognostic tool), and lymph node metastasis detection. These clinical applications run on a proprietary Foundation Engine designed for robust operation across variable sample quality, staining, and scanner conditions, and are delivered through the cloud-based Aiforia Platform with an integrated Clinical Suite Viewer. Aiforia also offers Aiforia Create, a collaborative cloud environment that allows pathologists and scientists to train custom deep learning models without prior AI expertise, alongside research solutions for preclinical and academic workflows and a veterinary diagnostics offering.

Revenue is generated primarily through annual and multi-year subscriptions for clinical AI deployments and research platform access, supplemented by professional services for enterprise implementations. Pricing is quote-based and tied to deployment scale, user counts, and integration requirements. The company pursues a dual go-to-market of direct enterprise field sales (targeting hospital pathology departments, academic medical centers, and pharma/biotech customers such as AP-HP, Mayo Clinic, Sanofi, Boehringer Ingelheim, and Charles River Laboratories) and channel partnerships with major healthcare IT vendors (Siemens Healthineers, Dedalus Group, Proscia, Tribun Health) plus regional partners in Canada (Quorum Technologies) and South Korea (Urban Datalab). The company maintains wholly-owned subsidiaries in France (Paris) and the United States (Cambridge, MA) to support European and North American commercial operations.

The company holds ISO 13485, ISO 27001, SOC 2 Type II, IVDR, GDPR, and HIPAA-aligned certifications and operates with a headcount of 51-100 employees. Management has disclosed a target of 50 clinical accounts and financial independence by end of 2027, alongside an ambition to cover approximately 80% of pathologists' diagnostic workflow by 2030.

Aiforia firmographics

Firmographics
Name
Aiforia
Legal name
Aiforia Technologies Oyj
Website
https://aiforia.com
Company type
Public
Founded year
2013
Operating status
Operating
Headcount range
51–100 employees
Short description
Aiforia Technologies Oyj (Nasdaq Helsinki: AFORIS) develops CE-IVD marked deep learning AI solutions for digital pathology, serving clinical laboratories, pharmaceutical and biotech firms, and academic medical centers across Europe, North America, and select Asia-Pacific markets.
Ownership category
akta.pro rank

Aiforia industry classification

Industry
Product category
Digital Pathology AI Software
NAICS
Software Publishers (5132), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (5182)
SIC
Surgical & Medical Instruments & Apparatus (3841), Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT

Keywords

  • Digital pathology AI
  • Clinical decision support
  • Medical image analysis
  • Cancer diagnostic software
  • Deep learning pathology

Where Aiforia is headquartered

Location

Headquarters

HQ city
Helsinki
HQ country
Finland
HQ region
Europe

Offices3 records

Markets served

Aiforia business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Clinical AI Solutions Subscription: SaaS subscription model providing access to CE-IVD marked AI diagnostic applications for clinical pathology laboratories. Revenue generated through software subscriptions with recurring annual or multi-year billing.
  2. Research Solutions Platform: Aiforia Create platform access for pharmaceutical researchers, biotech companies, and academic institutions to develop and deploy custom AI models for preclinical and clinical research applications.
  3. Professional Services: Implementation, training, and support services for enterprise deployments, particularly through strategic partnerships with Siemens Healthineers and Dedalus.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise clinical subscription
SubscriptionAnnualResearch platform subscription

Go-to-market motion3 records

Distribution channels7 records

Marketing channels8 records

Aiforia product offering

Product offering

Core offering

Aiforia develops and sells cloud-based deep learning AI software for digital pathology image analysis. Its offering consists of two main product lines: (1) CE-IVD marked Clinical Suites providing AI-driven diagnostic workflows for breast, lung, prostate, gastric, and colorectal cancer plus lymph node metastasis detection, and (2) Research Solutions including the Aiforia Create no-code AI model development platform for preclinical, pharmaceutical, and academic research. Both are powered by the proprietary Foundation Engine and delivered as SaaS to pathology laboratories, pharmaceutical/biotech companies, and academic medical centers.

Product overview

Aiforia offers a cloud-based AI platform for digital pathology with two main product lines: Clinical Solutions (CE-IVD marked AI diagnostic applications) and Research Solutions (for preclinical/academic use). The Clinical Suite portfolio includes specialized AI solutions for breast cancer, lung cancer, prostate cancer, gastric cancer, colorectal cancer (QuantCRC), and lymph node metastasis detection—all powered by the proprietary Foundation Engine technology. Aiforia® Create serves as the AI development tool enabling users to build custom deep learning models without coding. The platform integrates with various laboratory information systems and image management platforms through APIs and partnerships with Dedalus, Proscia, Siemens Healthineers, and Tribun Health.

Differentiator

Problem solved

Functional benefit

Brands

  • Aiforia® Clinical Suites: CE-IVD marked AI solutions for clinical diagnostics including Breast Cancer Suite, Lung Cancer Suite, Prostate Cancer Suite, Gastric Suite, and Lymph Node Metastasis detection
  • Aiforia® Create
  • Aiforia® Platform
  • Aiforia® Foundation Engine
  • Aiforia® Prostate Cancer Biopsy
  • Aiforia® Clinical Suite Viewer
  • QuantCRC

Products and services

  • Aiforia Clinical Suites Comprehensive portfolio of CE-IVD marked AI solutions for clinical diagnostics in digital pathology, providing fully automated case-centric workflows with a wide range of AI models and an optimized interactive user interface for pathology laboratories.
  • Aiforia Breast Cancer Suite

Quantifiable outcome

  • Clinical sector revenue grew 68% year-over-year in Q4 2025
  • +4 more outcomes

Companies that use Aiforia

Customer profile

Named customers16 records

Segments4 records

Ideal customer profiles4 records

Aiforia technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability3 records

Feature4 records

Aiforia partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered flagship, core and regional.

  • AP-HP (Assistance Publique-Hôpitaux de Paris)flagshipStrategic or Co-development Partner · 16 April 2026Aiforia selected as AI partner for the PROSTIA project led by AP-HP, deploying its CE-IVD-marked prostate cancer diagnostic solution across AP-HP pathology sites. Project expands from 2 hospitals (Bicêtre and Saint-Louis) to 7 total sites, covering all 3,000 prostate biopsy cases per year. Two-year initiative funded by Bpifrance through France 2030 program to evaluate medical, operational, and economic impacts of AI in pathology workflows.
  • ProsciacoreTechnology or Integration · 10 March 2026Non-exclusive partnership integrating Aiforia's AI-powered diagnostic applications with Proscia's Concentriq platform, enabling seamless AI-driven digital pathology workflows for anatomic pathology laboratories globally. Both companies have joined Proscia's Ready partner alliance and will showcase innovations at USCAP 115th Annual Meeting in March 2026.
  • Siemens HealthineerscoreChannel Partner/ Reseller/ Distributor · 9 September 2025Strategic partnership with Siemens Healthineers to expand availability of Aiforia's AI applications for clinical diagnostics across European diagnostic laboratories. Siemens Healthineers affiliates will co-market and sell Aiforia's digital pathology solutions as part of their broader portfolio, leveraging their strong regional presence and integration capabilities.
  • Dedalus GroupcoreTechnology or Integration · 1 September 2025Strategic alliance to integrate Aiforia's AI solutions into Dedalus' InVitro Anatomic Pathology Information System. The partnership aims to accelerate adoption of Aiforia's AI solutions among Dedalus' existing customer base of 5,700 laboratories and diagnostic centers worldwide by providing ready-made integration.
  • Quorum TechnologiesregionalChannel Partner/ Reseller/ Distributor · 18 March 2025Partnership to expand AI-assisted pathology solutions in Canada, improving digital pathology workflows and enhancing patient care by making AI solutions more accessible in the Canadian healthcare sector.
  • Urban DatalabregionalChannel Partner/ Reseller/ Distributor · 8 October 2024Partnership to promote AI-based digital pathology in South Korea, improving diagnostic accuracy, workflow efficiency, and patient care across South Korean hospitals.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Aiforia competitors and assessment

Company assessment

Direct peers

  • Paige.AI: Pure-play AI digital pathology company offering FDA-authorized clinical AI solutions and a research platform. Directly comparable to Aiforia in target market (clinical pathology labs and pharma), technology (deep learning on whole-slide images), and business model (SaaS subscriptions).
  • Ibex Medical Analytics: AI-powered cancer diagnostics platform for pathology, with CE-marked clinical products deployed across European hospitals. Closely comparable to Aiforia in CE-IVD clinical product portfolio, channel partnerships with tier-1 diagnostics vendors, and target customer segments.
  • PathAI: AI pathology company combining diagnostic products with biopharma services. Comparable to Aiforia across clinical AI applications, research/AI development tools (AISight), and pharmaceutical R&D use cases.
  • Owkin: AI-for-drug-discovery and pathology company serving both biopharma and clinical diagnostic customers. Comparable to Aiforia in using deep learning on pathology images for both pharma research and clinical decision support.

Emerging players

  • Proscia: Digital pathology platform vendor whose Concentriq platform integrates with Aiforia's AI solutions. Both partner and partial competitor with overlapping enterprise pathology customer base and cloud-based delivery model.
  • Tribun Health: Digital pathology image management vendor (CaloPix) that integrates with Aiforia through CaloPix Connect. Adjacent competitor and integration partner in enterprise pathology workflows.
  • Indica Labs: Pathology image analysis software vendor with both research (Halo) and emerging clinical offerings. Comparable in serving pharma and academic research customers and providing quantitative AI image analysis tooling.

Broad incumbents

  • Roche (Ventana Digital Pathology): Global diagnostics incumbent with a broad digital pathology portfolio spanning hardware, software, and AI. Comparable as a broader competitor with much greater scale and ability to bundle AI offerings with installed hardware base.
  • Philips Digital Pathology: Healthcare technology incumbent with IntelliSite digital pathology solution. Comparable as an enterprise-scale alternative that bundles whole-slide imaging, workflow software, and AI applications across hospital systems.
  • Leica Biosystems (Danaher): Major pathology equipment and software vendor (Aperio) now part of Danaher's diagnostics platform. Comparable as an established competitor in clinical pathology workflow infrastructure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Aiforia social profiles

Digital presence

Aiforia compliance and trust

Trust signal

Compliance6 records

Aiforia financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aiforia leadership team

Management profile

Number of profiles

Profiles17 records

Aiforia subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Aiforia funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aiforia M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aiforia

What does Aiforia do?

Aiforia develops and sells cloud-based deep learning AI software for digital pathology image analysis. Its offering consists of two main product lines: (1) CE-IVD marked Clinical Suites providing AI-driven diagnostic workflows for breast, lung, prostate, gastric, and colorectal cancer plus lymph node metastasis detection, and (2) Research Solutions including the Aiforia Create no-code AI model development platform for preclinical, pharmaceutical, and academic research. Both are powered by the proprietary Foundation Engine and delivered as SaaS to pathology laboratories, pharmaceutical/biotech companies, and academic medical centers.

Is Aiforia a public or private company?

Aiforia is a public company. It is classified as public and is currently operating.

When was Aiforia founded?

Aiforia was founded in 2013. It employs 51 to 100 people.

Where is Aiforia based?

Aiforia is headquartered in Helsinki, Finland, in the Europe region.

How does Aiforia make money?

Three revenue lines are on record. Clinical AI Solutions Subscription is the primary driver. The others are research Solutions Platform and professional Services.

Who are Aiforia's main competitors?

Direct peers on record are Paige.AI, Ibex Medical Analytics, PathAI and Owkin. Emerging players are Proscia, Tribun Health and Indica Labs. Broad incumbents are Roche (Ventana Digital Pathology), Philips Digital Pathology and Leica Biosystems (Danaher).

Does Aiforia have an API?

No public API is recorded for Aiforia.

What industry is Aiforia in?

Aiforia's product category is Digital Pathology AI Software. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 5132 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewAIFORIA: Clinical AI traction is building, but long implementations temper revenue conversionAiforia Technologies reported an investor update on Nov. 17, 2026, noting clinical AI adoption is early despite a 12% YoY digital pathology market forecast through 2031. The company cites 11 regulated solutions and 20+ clinical customers, but implementation delays and reimbursement uncertainty are tempering revenue conversion.Med-Tech InsightsPartnership expands access to precision diagnostics in oncologyStratipath and Aiforia announced a strategic partnership to integrate Stratipath Breast into Aiforia's Clinical Platform, giving laboratories access to both companies' breast cancer AI tools. The collaboration aims to expand access to AI-based precision diagnostics in Europe and worldwide, with joint go-to-market initiatives.FinanzNachrichten.deH1'26 review: costs above expectations; est. & PT chg.: Aiforia H1'26 results: revenue confirmed at ...Aiforia reported H1'26 revenue of €0.75m, down 46% year-on-year, with costs remaining elevated. Adjusted EBITDA was -€3.6m, and adjusted EBIT was -€6.5m. The company cut its FY26e EBITDA estimate to -€8.0m and its price target to €1.00.KauppalehtiPÖRSSI: Viikko päättyi nousuun, Aiforia romahtiHelsinki stock market closed with a small gain, with the OMXH general index up 0.37 percent, while Nokia rose 0.62 percent to 9.06 euros. Aiforia Technologies' loss widened on a disappointing half-year review, sending its shares down 16.96 percent to 1.038 euros. SRV led gains with a 3.9 percent rise, up over 70 percent in a month.KauppalehtiPÖRSSI: SRV jatkaa kovimpana nousijana, Aiforia romahti tulosjulkistuksen jälkeenHelsinki stock market rose 0.8% on Friday, with construction firm SRV leading gains at 6.7% and Nokia at 1.6%. Aiforia fell 18.6% after reporting a loss worse than expected, while Bittium began restructuring talks and YIT announced a new data center in Kouvola.KauppalehtiAiforian tappio syveni selvästi – Taustalla viivästykset asiakassopimuksissaHealth technology company Aiforia reported a first-half loss of 7.6 million euros, worse than analyst Inderes's 5.9 million euro forecast, with revenue falling to 0.8 million from 1.4 million. Operating loss was 4.7 million, and the order book dropped to 3.5 million from 5.1 million. The company signed a 20 million euro loan with the European Investment Bank and raised 6.4 million via a June share offering.InderesAiforia lands new partnership in breast cancer diagnosticsAiforia announced a strategic partnership with Stratipath to integrate Stratipath's AI-powered breast cancer risk profiling tool into its clinical platform. The integration aims to streamline pathology lab operations and potentially reduce the need for costly gene expression tests. Aiforia plans to build a comprehensive AI platform by integrating third-party models, though immediate growth depends on its own customer contracts.The European StingAiforia lands EU financing to develop AI-powered cancer detectionThe article discusses the financing secured by Aiforia to advance its development of AI-powered cancer detection technology. This funding from the European Union indicates significant strategic support for innovative healthcare solutions. Aiforia's work could have broader implications for cancer diagnosis and treatment methodologies in the future.Health Tech WorldAiforia secures €20 million for AI-powered cancer diagnosticsHelsinki-based life-science company Aiforia has secured €20 million in venture debt from the European Investment Bank to fund the development of its AI-powered cancer diagnostics platform and support commercial operations. The financing, facilitated through the European Commission’s InvestEU programme, is structured in three tranches contingent on meeting specific revenue targets and includes a synthetic warrant arrangement to avoid immediate shareholder dilution.FundsforngosAiforia Secures €20 Million EU Financing to Advance AI-Powered Cancer DetectionAiforia, a Finnish digital pathology company, secured €20 million in venture debt from the European Investment Bank to enhance its AI-powered cancer detection platform. The funding aims to accelerate product development, expand globally, and improve diagnostics using AI technology. The investment supports European efforts to advance healthcare technology and competitiveness.